These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 30146693)

  • 1. Soluble PD-1 and PD-L1 as potential biomarkers for classical Hodgkin lymphoma.
    da Silva PB; Real JM; Ferreira LRP; Esteves GH; Brito FDN; Baiocchi OCG
    Hematol Oncol; 2018 Oct; 36(4):709-712. PubMed ID: 30146693
    [No Abstract]   [Full Text] [Related]  

  • 2. Soluble programmed cell death protein 1 (sPD-1) and the soluble programmed cell death ligands 1 and 2 (sPD-L1 and sPD-L2) in lymphoid malignancies.
    Mortensen JB; Monrad I; Enemark MB; Ludvigsen M; Kamper P; Bjerre M; d'Amore F
    Eur J Haematol; 2021 Jul; 107(1):81-91. PubMed ID: 33721375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of PD-1 and PD-L1 increase in consecutive biopsies in patients with classical Hodgkin lymphoma.
    Hollander P; Amini RM; Ginman B; Molin D; Enblad G; Glimelius I
    PLoS One; 2018; 13(9):e0204870. PubMed ID: 30261066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Use of Programmed Cell Death-1 and Its Ligand Expression as Discriminatory and Predictive Markers in Ovarian Cancer.
    Chatterjee J; Dai W; Aziz NHA; Teo PY; Wahba J; Phelps DL; Maine CJ; Whilding LM; Dina R; Trevisan G; Flower KJ; George AJT; Ghaem-Maghami S
    Clin Cancer Res; 2017 Jul; 23(13):3453-3460. PubMed ID: 27986748
    [No Abstract]   [Full Text] [Related]  

  • 5. [Distribution and Clinical Significance of CTLA-4, PD-1 and PD-L1 in Peripheral Blood of Patients with Small Cell Lung Cancer].
    Li H; Liu Y; Liu Y; Liu J; Zhao D; Wang Y; Cheng Y
    Zhongguo Fei Ai Za Zhi; 2017 Nov; 20(11):755-760. PubMed ID: 29167005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble programmed death-ligand 1 are highly expressed in peripheral T-cell lymphoma: a biomarker for prognosis.
    Shen H; Ji Y; Zhou D; Zhang Y; Wang W; Sun J; Zhang W
    Hematology; 2019 Dec; 24(1):392-398. PubMed ID: 30890046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analytical performance of a new automated chemiluminescent magnetic immunoassays for soluble PD-1, PD-L1, and CTLA-4 in human plasma.
    Goto M; Chamoto K; Higuchi K; Yamashita S; Noda K; Iino T; Miura M; Yamasaki T; Ogawa O; Sonobe M; Date H; Hamanishi J; Mandai M; Tanaka Y; Chikuma S; Hatae R; Muto M; Minamiguchi S; Minato N; Honjo T
    Sci Rep; 2019 Jul; 9(1):10144. PubMed ID: 31300681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of circulating PD-1 and PD-L1 as diagnostic biomarkers in dogs with tumors.
    Song DW; Ro WB; Park HM
    J Vet Sci; 2021 Sep; 22(5):e75. PubMed ID: 34553519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The content of the soluble forms PD-1 and PD-L1 in blood serum of patients with gastric cancer and their relationship with clinical and morphological characteristics of the disease.].
    Gershtein ES; Ognerubov NA; Chang VL; Delektorskaya VV; Korotkova EA; Sokolov NY; Polikarpova SB; Stilidi IS; Kushlinskii NE
    Klin Lab Diagn; 2020; 65(6):347-352. PubMed ID: 32459892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble PD-L1 is a promising disease biomarker but does not reflect tissue expression in classic Hodgkin lymphoma.
    Veldman J; Alsada ZND; van den Berg A; Plattel WJ; Diepstra A; Visser L
    Br J Haematol; 2021 May; 193(3):506-514. PubMed ID: 33620088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The concentration of programmed cell death-ligand 1 in the peripheral blood is a useful biomarker for esophageal squamous cell carcinoma.
    Akutsu Y; Murakami K; Kano M; Toyozumi T; Matsumoto Y; Takahashi M; Otsuka R; Sekino N; Yokoyama M; Shiraishi T; Matsubara H
    Esophagus; 2018 Apr; 15(2):103-108. PubMed ID: 29892935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression pattern of PD-L1 and PD-L2 in classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, and gray zone lymphoma.
    Tanaka Y; Maeshima AM; Nomoto J; Makita S; Fukuhara S; Munakata W; Maruyama D; Tobinai K; Kobayashi Y
    Eur J Haematol; 2018 May; 100(5):511-517. PubMed ID: 29377256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble programmed cell death protein-1 and programmed cell death ligand-1 in sepsis.
    Banerjee D; Monaghan S; Zhao R; Walsh T; Palmisciano A; Phillips GS; Opal S; Levy MM
    Crit Care; 2018 Jun; 22(1):146. PubMed ID: 29875013
    [No Abstract]   [Full Text] [Related]  

  • 14. PD-1 and PD-L1 Immunohistochemistry as a Diagnostic Tool for Classic Hodgkin Lymphoma in Small-volume Biopsies.
    Uccella S; Magnoli F; Vivian LF; Marchiori D; Leoni E; Tibiletti MG; Sessa F
    Am J Surg Pathol; 2021 Sep; 45(9):1293-1296. PubMed ID: 33399337
    [No Abstract]   [Full Text] [Related]  

  • 15. Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma.
    Han X; Gu YK; Li SL; Chen H; Chen MS; Cai QQ; Deng HX; Zuo MX; Huang JH
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):303-312. PubMed ID: 30267213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Expression of soluble programmed death-1, soluble programmed death ligand 1 proteins and immune status in patients with oral lichen planus].
    Luo L; Shu M; Li S; Cai Y
    Zhonghua Kou Qiang Yi Xue Za Zhi; 2015 Oct; 50(10):585-9. PubMed ID: 26757624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response To: PD-1 and PD-L1 Immunohistochemistry as a Diagnostic Tool for Classic Hodgkin Lymphoma in Small-volume Biopsies.
    Volaric AK; Gru AA
    Am J Surg Pathol; 2021 Sep; 45(9):1296-1297. PubMed ID: 34081039
    [No Abstract]   [Full Text] [Related]  

  • 18. PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.
    Roemer MG; Advani RH; Ligon AH; Natkunam Y; Redd RA; Homer H; Connelly CF; Sun HH; Daadi SE; Freeman GJ; Armand P; Chapuy B; de Jong D; Hoppe RT; Neuberg DS; Rodig SJ; Shipp MA
    J Clin Oncol; 2016 Aug; 34(23):2690-7. PubMed ID: 27069084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-1 /PD-L1 checkpoint in hematological malignancies.
    Annibali O; Crescenzi A; Tomarchio V; Pagano A; Bianchi A; Grifoni A; Avvisati G
    Leuk Res; 2018 Apr; 67():45-55. PubMed ID: 29428449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies.
    Gravelle P; Burroni B; Péricart S; Rossi C; Bezombes C; Tosolini M; Damotte D; Brousset P; Fournié JJ; Laurent C
    Oncotarget; 2017 Jul; 8(27):44960-44975. PubMed ID: 28402953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.